Piritrexim

DB03695InvestigationalSmall molecule

Piritrexim has been used in trials studying the treatment of Bladder Cancer, Urethral Cancer, and Transitional Cell Cancer of the Renal Pelvis and Ureter.

Mechanism: Pharmacologically active on Dihydrofolate reductase
Curator reviewed
Formula / weight: C₁₇H₁₉N₅O₂ · 325.3651 g/mol (avg)
Code names: BW-301U

Resolves to

Compound

UNIIMK2A783ZUTCAS72732-56-0ChEMBLCHEMBL7492PubChem54369

Structure

InChIKeyVJXSSYDSOJBUAV-UHFFFAOYSA-NSMILESCOC1=CC(CC2=C(C)C3=C(N=C2)N=C(N)N=C3N)=C(OC)C=C1

Targets

P00374DHFR

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

48Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Piritrexim, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account